Subcutaneous ICD therapy
Gottsegen György Országos Kardiovaszkuláris Intézet,
Felnőtt Kardiológiai Osztály, Elektrofiziológiai és Pacemakerterápiás Részleg,
Dr. Som Zoltán, Gottsegen György Országos Kardiovaszkuláris Intézet, Felnőtt Kardiológiai Osztály, Elektrofiziológiai és Pacemakerterápiás Részleg, 1096 Budapest, Haller u. 29. E-mail: email@example.com
The subcutaneous ICD was designed in 2009 to overcome the limitations of transvenous ICD (TV-ICD). Since it’s introduction, numerous clinical studies were conducted to ensure the effectivity and safety of the S-ICD. Based on the result of these trials, the S-ICD is an integral part of the primary or secondary prevention of sudden cardiac death in the recent guidelines. During it’s course, there were some substantial changes in the hardver and in the softver of the device, more effective rhythm discrimination algorhythms were developed. The implantation technique, the anaesthesia methods during implantation also changed and became more simpler. Based on these developments, all the surgical and the electrophysiologic complications of the system decreased and the S-ICD became part of the everyday practice. Until now, the antibradycardia and antitachycardia pacing with S-ICD is not possible, which is the most important problem to solve in the near future. This review summarizes the modern S-ICD therapy based on the newest trials in this field.
ISSUE: CARDIOLOGIA HUNGARICA | 2023 | VOLUME 53, ISSUE 3
|Watch the video summary|